Razvan Galalae

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer

Razvan Galalae, Alvaro A. Martinez, Tim Mate et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 225 citations

Medicine, Oncology, Urology +17

Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer

Razvan Galalae, Gyoergy Kovács, Juergen Schultze et al. · International Journal of Radiation Oncology*Biology*Physics · 2002 · 196 citations

Medicine, Oncology, Radiation Oncology +17

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime

Alvaro A. Martinez, D. Jeffrey Demanes, Razvan Galalae et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 73 citations

Medicine, Oncology, Urology +16

CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer

Derya Tilki, Ster Irmak, Leticia Oliveira‐Ferrer et al. · Oncogene · 2006 · 64 citations

Medicine, Cancer Biology, Oncology +15

Hypofractionated Conformal HDR Brachytherapy in Hormone Naïve Men with Localized Prostate Cancer

Razvan Galalae, Alvaro A. Martinez, Nils Nuernberg et al. · Strahlentherapie und Onkologie · 2006 · 50 citations

Medicine, Oncology, Surgery +2